Seeking Alpha
15 Sept 2026, 11:30 UTC · 1h ago
Verdict
Source says Upgrade. We score BSX +0.90 across two claims.
Score confirms the headline.
Upgrade
Rating stated in the headline
+0.90strongly bullish
What the story claims
2 claims · scored −1 bearish … +1 bullish · 0 new · 2 priced in
Boston Scientific is trading at a forward P/E of 13.1, which is below its historical average.
Priced inanalysis of historical multiples and current price
So whatA return to its historical average multiple would imply a significant double-digit percentage increase in share price.
More positive than 77% of claims this week
The company's growth headwinds in WATCHMAN and electrophysiology are being offset by momentum in Interventional Cardiology and Vascular Therapies.
Continue reading
5 related stories
More positive than 95% of ticker scores this week
Scored by the NIS engine · methodology.
Top 2 movers · tap to explore
Priced inanalysis of Q2 2026 results
So whatThe balance between these segments will determine if the company can maintain its current revenue growth trajectory through FY2027.
More positive than 66% of claims this week
Which stocks this story touches
More positive than 95% of ticker scores this week
The company was upgraded to 'Strong Buy' due to an attractive valuation, robust profitability, and strategic acquisitions.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Globe News Wire
2h ago
—
No price for BSX right now — the quote feed didn't answer.
BSX chart →
